Announced Date: 2025-09-17 (September 17, 2025) Asset Name: 2MW7141 Licensor (Seller): Mabwell Bio (China) Licensee (Buyer): … [China BD 2025] Mabwell and Kalexo enters License on siRNA Program 2MW7141Read more
China NewCo
[China BD 2025] Hengrui and Braveheart Bio (NewCo) enters a 1 billion USD license on Myosin inhibitor HRS-1893
Announced Date: 2025-09-05 (September 5, 2025) Asset Name: HRS-1893 Licensor: Jiangsu Hengrui Pharmaceuticals (China) Licensee (Buyer): … [China BD 2025] Hengrui and Braveheart Bio (NewCo) enters a 1 billion USD license on Myosin inhibitor HRS-1893Read more
[China BD 2025] Qyuns and Caldera Entered a License for Bispecific Antibody QX030N
Announced Date: 2025-04-23 (April 23, 2025) Asset Name: QX030N Licensor (Seller): Qyuns Therapeutics (China) Licensee (Buyer): … [China BD 2025] Qyuns and Caldera Entered a License for Bispecific Antibody QX030NRead more
[China NewCo 2024] Hengrui and Hercules CM NewCo enters a license on 4 GLP-1 Programs
Announced Date: 2024-08-29 (May 29, 2024) Key Asset: Four GLP-1 Programs, HRS9531 (KAI-9531)、HRS-7535 (KAI-7535)、HRS-4729 (KAI-4729) Licensor: … [China NewCo 2024] Hengrui and Hercules CM NewCo enters a license on 4 GLP-1 ProgramsRead more